Based on the paradigm of breast cancer, most clinical trials evaluating trastuzumab in patients with NSCLC have required evidence of protein overexpression or gene amplification rather than the detection of specific HER2 gene mutations. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.